Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

<ns4:p>Africa bears the brunt of many of the world’s most devastating human and animal infectious diseases, a good number of which have no licensed or effective vaccines available. The continent’s potential to generate novel interventions against these global health threats is however largely untapped. Strengthening Africa’s vaccine research and development (R&amp;D) sector could accelerate discovery, development and deployment of effective countermeasures against locally prevalent infectious diseases, many of which are neglected and have the capacity to spread to new geographical settings. Here, we review Africa’s human and veterinary vaccine R&amp;D sectors and identify key areas that should be prioritized for investment, and synergies that could be exploited from Africa’s veterinary vaccine industry, which is surprisingly strong and has close parallels with human vaccine R&amp;D.</ns4:p>

Original publication




Journal article


AAS Open Research


F1000 Research Ltd

Publication Date





18 - 18